Health
Pancreatitis drug blocks SARS-CoV-2 activators in the upper respiratory tract – News-Medical.Net
Pancreatitis drug Camostat inhibits new SARS-CoV-2 activators identified in the upper respiratory tract.
There are no therapeutics available that have been developed…
Pancreatitis drug Camostat inhibits new SARS-CoV-2 activators identified in the upper respiratory tract.
There are no therapeutics available that have been developed for COVID-19 treatment. Repurposing already available medication for COVID-19 therapy is an attractive option to shorten the road to treatment development.
The drug Camostat could be suitable. Camostat exerts antiviral activity by blocking the protease TMPRSS2, which is used by SARS-CoV-2 for entry into cells.
However, it was previously…
-
General20 hours agoAustralia Kangaroos lose Xavier Coates and Zac Lomax ahead of rugby league Ashes in England
-
Business24 hours agoDoes Macquarie rate Karoon Energy shares a buy, hold or sell?
-
General6 hours agoPolice investigating after body found on road in Newborough, Gippsland
-
Noosa News17 hours agoDeaths of Karen Edwards, Tim Thomson, and Gordon Twaddle re-examined in inquest